Term
| which Dopamine receptors increase cAMP, which decrease cAMP |
|
Definition
D1 and D3 increase cAMP
D2, D3, and D4 decrease cAMP |
|
|
Term
|
Definition
| Phenothiazines, butyrphenones, thioxanthenes, benzamides |
|
|
Term
|
Definition
D2 blockers
"azines"
interact w/ many receptors so many SEs
-H1 - sedation/weight gain
-Mblocker - dry mouth, medriasis, bronchial dilation, tachycardia, constipation, urine retention
-D2 blocker - extrapyramidal SEs
-Alpha blocker - hypotension
-torsades |
|
|
Term
|
Definition
D2 blockers
use - pruritis, motion sickness, sedative
"coast guard cocktail" - for motion sickness |
|
|
Term
|
Definition
D2 blocker
use - drug induced nausea and migraine |
|
|
Term
|
Definition
D2 blocker
antipsychotic
used for long term treatment |
|
|
Term
|
Definition
D2 blockers
more D2 specific than phenothiazines and non-trycyclic |
|
|
Term
|
Definition
D2 blocker - butryphenone
very selective for D2
EPS; dystonic reaction, akinesia, rigidity, tremors, akathisia and tarditive dyskinesia |
|
|
Term
| pseudo-parkinsonism? treatments? |
|
Definition
extrapyramidal symptoms from blocking dopamine -> too much ACh
Tx - anticholinergics: benztropine, trihexiphenidyl, diphenhydramine, amantadine (antiviral) |
|
|
Term
| name the atypical antipsychotics and their metabolism |
|
Definition
Clonzapine - 1A2
Olanzapine - 1A2
Risperidone - 2D6/3A4
Aripiprazole - 2D6/3A4
Quetiapine - 3A4
Ziprasidone - 3A4
Amisulpirid - not metabolized |
|
|
Term
|
Definition
anticholinergic
anti-parkinson agent
SE - dystonia |
|
|
Term
|
Definition
anticholinergic
anti parkinsonian agent |
|
|
Term
|
Definition
antihistamine and anticholinergic
anti-parkinsonian agent |
|
|
Term
|
Definition
antiviral
anti-parkinson agent |
|
|
Term
|
Definition
atypical antipsychotic
Low D2, high D4 affinity and 5HT2 antagonist
CYP 1A2 metabolism
SE - agranulocytosis, hypersalivation and hyperthermia, seizures, weight gain (10x10), trycyclic effects |
|
|
Term
|
Definition
atypical antipsychotic
low D2, high D4, 5HT2 antagonist
CYP 1A2 metabolism
SEs - (clozapine w/ NO agranulocytosis) hypersalivation, hyperthermia, seizures, weight gain, trycyclic effects |
|
|
Term
|
Definition
atypical antipsychotic
5HT2 antagonist, NaSRI
3A4 metabolism
SE - QT prolongation - torsades |
|
|
Term
|
Definition
atypical antipsychotic
equal D2 blocker and 5HT2 blocker
3A4 metabolism
SEs - sedation, cataract development and hypothyroidism |
|
|
Term
|
Definition
5HT2 antagonist, 5HT 1A partial agonist, D2 partial agonist,
2D6/3A4 metabolism
Less weight gain |
|
|
Term
| Parkinson therapy mechanisms |
|
Definition
| increase DA by giving DA or a DA-R agonist |
|
|
Term
| 2 classes of DA receptor agonsits? examples? SEs |
|
Definition
Ergotamine Derivatives - Bromcriptone and Pergolide. SEs - hallucinations, psychosis, confusion, N&V, postural hypotensioin, fibrosis, vasospasm, GI ulceration
Non-ergotamine derivatives
Pramipexole and Ropinrole
SEs - hallucinations, psychosis, confusion, N&V, postural hypotension, GI ulceration, NO fibrosis, NO vasospasm |
|
|
Term
|
Definition
DA receptor agonist, Ergotamine derivative
Parkinson Disease |
|
|
Term
|
Definition
DA receptor agaonist, non-ergotamine derivative
Parkinson Disease |
|
|
Term
|
Definition
DA receptor agonist, non-ergotamine derivative
Parkinson Disease |
|
|
Term
|
Definition
COMT inhibitor (prevents inactivation of levodopa in brain)
Parkinson diseease tx |
|
|
Term
|
Definition
| inhibits DDC, allowing levodopa to go to brain |
|
|
Term
| Stabilizing levodopa (Stalevo) |
|
Definition
| carbidopa, levodopa, and entacapone |
|
|
